All News

This week, the top managed care news included bipartisan Senate bills taking aim at drug prices, especially insulin; a study linking payer refusal to pay for proprotein convertase subtilisin/kexin type 9 inhibitors with heart attacks and deaths; and a former FDA commissioner visiting The American Journal of Managed Care®.

Amid a contentious debate, the Senate Finance Committee voted 19-9 to advance legislation introduced by Senators Chuck Grassley, R-Iowa, and Ron Wyden, D-Oregon, to rein in drug costs in Medicare and Medicaid; a House of Representatives subcommittee accused Juul Labs, maker of the ubiqutious e-cigarette device blamed for a youth vaping epidemic, of targeting children through health promotion activities at about a half dozen schools and summer camps; at their annual meeting this week, governors from around the country are discussing what they will do if a federal appeals court invalidates the Affordable Care Act.

The prevalence of chronic obstructive pulmonary disease (COPD) was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.

A recently published study used linguistic analysis to investigate communication gaps between patients with Parkinson disease and physicians about off periods using a database containing dialogues recorded during regular office visits. Not only did the recordings show 4 specific areas that need improvement, they also showed a care gap between what the physicians thought they did and what actually happened.

Nivolumab (Opdivo) monotherapy is currently indicated for the treatment of patients with hepatocellular carcinoma who were previously treated with the targeted therapy sorafenib, sold as Nexavar, based on the CheckMate 040 trial. Assessing the safety and efficacy of nivolumab in combination with ipilimumab (Yervoy) among these patients, researchers have observed clinically meaningful responses and an acceptable safety profile.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text